Semaglutide, the ingredient in Ozempic and Wegovy, will soon move to generic status in Canada and consultants hope this sparks plan sponsors to take a proactive approach to weight management
Employers urged to address stigma and rethink benefits for workers with obesity
Specialty pharma claims triple as pharmacists fill gaps in primary care, TELUS Health report finds
Province reopens review of insurer-pharmacy deals while regulator holds off on decision
Wegovy claims soared 91% in 2024 as insurers weigh coverage limits and rising plan costs
Wegovy drives 91% spike in Canadian drug claims while Zepbound outperforms in US clinical trial
